Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Clene Inc.

CLNN
Current price
4.4 USD +0.24 USD (+5.77%)
Last closed 4.16 USD
Company clene.com
ISIN US1856341029
Sector Consumer Defensive
Industry Packaged Foods
Exchange NASDAQ
Capitalization 32 716 892 USD
Yield for 12 month -41.83 %
1Y
3Y
5Y
10Y
15Y
CLNN
21.11.2021 - 28.11.2021

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. Address: 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

45.17 USD

P/E ratio

Dividend Yield

Current Year

+654 000 USD

Last Year

+473 000 USD

Current Quarter

+87 000 USD

Last Quarter

+91 000 USD

Current Year

+533 000 USD

Last Year

+447 000 USD

Current Quarter

+69 000 USD

Last Quarter

+73 000 USD

Key Figures CLNN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -34 400 000 USD
Operating Margin TTM -8121.98 %
PE Ratio
Return On Assets TTM -41.71 %
PEG Ratio
Return On Equity TTM -289.66 %
Wall Street Target Price 45.17 USD
Revenue TTM 442 000 USD
Book Value 2.09 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -66.2 %
Dividend Yield
Gross Profit TTM 447 000 USD
Earnings per share -5.29 USD
Diluted Eps TTM -5.29 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 61.4 %
Profit Margin

Dividend Analytics CLNN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLNN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 11.07.2024
Dividend Date

Stock Valuation CLNN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 97.2752
Price Sales TTM 74.0201
Enterprise Value EBITDA -1.1292
Price Book MRQ 7.8325

Financials CLNN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CLNN

For 52 weeks

3.82 USD 12 USD
50 Day MA 5.14 USD
Shares Short Prior Month 127 257
200 Day MA 6.44 USD
Short Ratio 1.9
Shares Short 160 404
Short Percent 2.24 %